(S)-tert-butyl 4-(1-fluoro-2-hydroxyethyl)piperidine-1-carboxylate | 1280608-32-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (S)-tert-butyl 4-(1-fluoro-2-hydroxyethyl)piperidine-1-carboxylate
• 英文别名: Tert-butyl (S)-4-(1-fluoro-2-hydroxyethyl)piperidine-1-carboxylate；tert-butyl 4-[(1S)-1-fluoro-2-hydroxyethyl]piperidine-1-carboxylate
• CAS: 1280608-32-3
• 化学式: C₁₂H₂₂FNO₃
• 分子量: 247.31
• InChiKey: QGEYVOBSVRXLBI-SNVBAGLBSA-N

物化性质

• 沸点：
  342.8±12.0 °C(Predicted)
• 密度：
  1.107±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (S)-tert-butyl 4-(1-fluoro-2-hydroxyethyl)piperidine-1-carboxylate 在 叠氮磷酸二苯酯 、 10% palladium on activated charcoal 、 氢气 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Design and evaluation of a 2-(2,3,6-trifluorophenyl)acetamide derivative as an agonist of the GPR119 receptor

  摘要：

  The design and synthesis of a GPR119 agonist bearing a 2-(2,3,6-trifluorophenyl)acetamide group is described. The design capitalized on the conformational restriction found in N-beta-fluoroethylamide derivatives to help maintain good levels of potency while driving down both lipophilicity and oxidative metabolism in human liver microsomes. The chemical stability and bioactivation potential are discussed. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.088
• 作为产物：
  描述：

  4-(2-氧代乙基)哌啶-1-羧酸叔丁酯 在 sodium tetrahydroborate 、 (5R)-(+)-2,2,3-trimethyl-5-benzyl-4-imidazolidinone dichloroacetic acid 、 N-氟代双苯磺酰胺 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 异丙醇 为溶剂， 反应 7.0h， 生成 (S)-tert-butyl 4-(1-fluoro-2-hydroxyethyl)piperidine-1-carboxylate
  参考文献：
  名称：

  SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE

  摘要：

  本发明提供了式（I）的化合物 其中R 1 ，R 2 ，R 3 和R 4 具有规范中定义的任何值，以及其药学上可接受的盐，这些化合物在治疗由CFTR介导和调节的疾病和症状中是有用的，包括囊性纤维化、Sjögren综合征、胰腺功能不全、慢性阻塞性肺病和慢性阻塞性气道疾病。还提供了由一个或多个式（I）的化合物组成的药物组合物。

  公开号：

  US20170101406A1

文献信息

• [EN] N-SULFONYLATED PYRAZOLO[3,4-B]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE<br/>[FR] PYRAZOLO[3,4-B]PYRIDIN-6-CARBOXAMIDES N-SULFONYLÉS ET LEUR PROCÉDÉ D'UTILISATION
  申请人：ABBVIE S Á R L

  公开号：WO2017060874A1

  公开（公告）日：2017-04-13

  The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

  本发明提供了一种具有以下结构的化合物（I），其中R1、R2、R3、R4、R5和R6具有规范中定义的任何值，以及其药学上可接受的盐，这些化合物在治疗由CFTR介导和调节的疾病和症状中是有用的，包括囊性纤维化、Sjögren综合征、胰腺功能不全、慢性阻塞性肺病和慢性阻塞性气道疾病。还提供了由一个或多个具有结构（I）的化合物组成的药物组合物。
• SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE
  申请人：AbbVie S.à.r.l.

  公开号：US20170101406A1

  公开（公告）日：2017-04-13

  The present invention provides for compounds of formula (I) wherein R 1 , R 2 , R 3 , and R 4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

  本发明提供了式（I）的化合物 其中R 1 ，R 2 ，R 3 和R 4 具有规范中定义的任何值，以及其药学上可接受的盐，这些化合物在治疗由CFTR介导和调节的疾病和症状中是有用的，包括囊性纤维化、Sjögren综合征、胰腺功能不全、慢性阻塞性肺病和慢性阻塞性气道疾病。还提供了由一个或多个式（I）的化合物组成的药物组合物。
• [EN] COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF IRAK-4<br/>[FR] COMPOSÉS ET PROCÉDÉS POUR LA DÉGRADATION CIBLÉE DE L'IRAK-4
  申请人：ARVINAS OPERATIONS INC

  公开号：WO2022266258A1

  公开（公告）日：2022-12-22

  This application relates to a bifunctional compound having the structure of Formula (I): ITM-LNK-CLM (I), or a pharmaceutically acceptable salt, solvate, enantiomer, stereoisomer, or isotopic derivative thereof, which contains, on one end, a cereblon E3 ubiquitin ligase that binds to the E3 ubiquitin ligase and, on the other end, a moiety that binds the target protein, Interleukin-1 Receptor-Associated Kinase 4 (IRAK-4), such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The bifunctional compounds of the present disclosure present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from cellular signaling mediated by the target protein are treated or prevented with bifunctional compounds and compositions of the present disclosure.

  本申请涉及一种具有式(I)结构的双功能化合物：ITM-LNK-CLM(I)，或其药学上可接受的盐、溶剂合物、对映体、立体异构体或同位素衍生物，其一端含有结合E3泛素连接酶的谷氨酰胺酰化酶（Cereblon E3 ubiquitin ligase），另一端含有结合目标蛋白Interleukin-1 Receptor-Associated Kinase 4 (IRAK-4)的基团，使目标蛋白靠近泛素连接酶以实现目标蛋白的降解和抑制。本公开的双功能化合物展示了与目标蛋白的降解/抑制相关的广泛药理活性。使用本公开的双功能化合物和组合物治疗或预防由目标蛋白介导的细胞信号传导引起的疾病或障碍。
• N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
  申请人：AbbVie S.à.r.l.

  公开号：US10259810B2

  公开（公告）日：2019-04-16

  The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

  本发明提供了式 (I) 的化合物 其中 R1、R2、R3、R4、R5 和 R6 具有说明书中定义的任一值，及其药学上可接受的盐，可作为治疗由 CFTR 介导和调节的疾病和病症的药物，包括囊性纤维化、Sjögren 综合征、胰腺功能不全、慢性阻塞性肺病和慢性阻塞性气道疾病。还提供了由一种或多种式（I）化合物组成的药物组合物。
• N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
  申请人：AbbVie S.à.r.l.

  公开号：US10647717B2

  公开（公告）日：2020-05-12

  The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

  本发明提供了式 (I) 的化合物 其中 R1、R2、R3、R4、R5 和 R6 具有说明书中定义的任一值，及其药学上可接受的盐，可作为治疗由 CFTR 介导和调节的疾病和病症的药物，包括囊性纤维化、Sjögren 综合征、胰腺功能不全、慢性阻塞性肺病和慢性阻塞性气道疾病。还提供了由一种或多种式（I）化合物组成的药物组合物。